Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

NCT05887492 is registered in ClinicalTrials.gov with Tango Therapeutics, Inc. as lead sponsor.

NCT NCT05887492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05887492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Lead sponsor
Tango Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 12, 2023
Completion date
September 30, 2026
Enrollment
126 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, lung cancer, non small cell lung cancer, solid tumors, adult